{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287974,0.001181378,0.002264216,0.000287398,0.0003047606,0.001052349,0.000757686,0.001575787,0.004668729],"category_scores_gemma":[0.00151519,0.0005328783,0.002323075,0.000304987,0.0009018492,0.001014309,0.0003563082,0.00318503,0.0007976077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008749823,"about_ca_system_score_gemma":0.0007385144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001245803,"about_ca_topic_score_gemma":0.00323372,"domain_scores_codex":[0.9995334,0.000266114,0.00002098991,0.00007855015,0.00002465633,0.00007625762],"domain_scores_gemma":[0.99938,0.0002167655,0.0001159185,0.00004502973,0.00003359313,0.0002087002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9747882,0.003232023,0.0007450425,0.0006180034,0.001150378,0.00003686139,0.00005489419,0.000455368,0.001718183,0.0001138567,0.0009111848,0.01617604],"study_design_scores_gemma":[0.9433854,0.05296362,0.001582022,0.00004171962,0.0005183443,0.00002796396,0.00002767848,0.0004429325,0.0002413988,0.0001881716,0.0005666455,0.00001417169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895294,0.004473193,0.0003984792,0.0008100087,0.0006925181,0.001541807,0.0007464513,0.00008765172,0.001720464],"genre_scores_gemma":[0.9911916,0.001974671,0.0007296998,0.001088308,0.0002739143,0.001244984,0.0007534458,0.00002094508,0.002722509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004668729,"threshold_uncertainty_score":0.0156185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05803676378711036,"score_gpt":0.3752254400827541,"score_spread":0.3171886762956437,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}